Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1081735

registered interest
date	04/03/2019
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	World War II: Veterans
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Defence, how much his Department spends annually on health and welfare services for veterans of World War Two.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	228011
answer	answer is ministerial correction date of answer 12/03/2019 answer text <p>Once Armed Forces personnel leave service, the provision of their health and welfare needs are primarily provided by the Department of Health and Social Care, and the Department for Work and Pensions.</p><p>Some welfare support is provided by the Ministry of Defence's Veterans UK organisation, but it is not possible to separate out costs for those veterans who served in World War Two.</p> answering member constituency Bournemouth East answering member printed Mr Tobias Ellwood question first answered 12/03/2019 15:58:28 answering member 1487 label Biography information for Mr Tobias Ellwood
tabling member	1522 label Biography information for Adam Holloway

1054826

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make representations to Sanofi Pasteur on undertaking new research into the risks of adverse events, including psychosis, from using the vaccine Stamaril.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216210
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216211 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1054828

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations he has made to Sanofi Pasteur on ensuring that new technology is developed to eliminate the risks of adverse events, including psychosis, from the use of the vaccine Stamaril.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216211
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216210 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1054829

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will commission research into new vaccines for yellow fever in the event that Sanofi Pasteur does not undertake research into its yellow fever vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216212
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the development of cheaper vaccines. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p><p> </p><p>The NIHR and the Medical Research Council both have a wide portfolio of research activity in vaccines which cover clinical trials for new vaccines, new technologies, ways of improving uptake and cost effectiveness.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 12/02/2019 16:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1522 label Biography information for Adam Holloway

1054830

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including psychosis in the list of potential side effects published on the use of Stamaril as a vaccine for yellow fever.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216213
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216210 216211 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1054831

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits on including yellow fever in the list of vaccines under the Vaccine Damage Payment Act 1979 for which compensation may be paid.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216214
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Vaccine Damage Payment Scheme (VDPS) is not a compensation scheme. There is no assessment of what losses were actually suffered. It provides a one off tax-free lump sum payment, currently £120,000, to successful claimants and is one part of the wide range of support and help available to severely disabled people in the United Kingdom.</p><p> </p><p>The VDPS is primarily designed to cover adverse reactions for vaccination in the child immunisation programme which is a Government initiative to protect the community from infectious disease and does not include travel vaccines.</p><p> </p><p>The Scheme is being kept under review if further inclusions are thought necessary.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 11:47:07 answering member 4067 label Biography information for Steve Brine
tabling member	1522 label Biography information for Adam Holloway

1054838

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vaccination: Compensation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of changing the provisions of the Vaccine Damage Payment compensation scheme so that people who suffer a psychiatric injury as a result of an adverse event involving a vaccine can also be fairly compensated for the effects of (a) loss of earnings, (b) the stigma of mental illness and (c) incarceration.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216215
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Department for Work and Pensions administers the Vaccine Damage Payment Scheme (VDPS) on our behalf.</p><p> </p><p>The VDPS is not a compensation scheme. There is no assessment of what losses were actually suffered. It provides a one off tax-free lump sum payment, currently £120,000, to successful claimants and is one part of the wide range of support and help available to severely disabled people in the United Kingdom.</p><p> </p><p>This Scheme is not designed as an alternative to litigation and does not prejudice the right of the injured person to pursue a claim against the manufacturer of the vaccine for compensation.</p><p> </p><p>To qualify for a VDPS payment, the applicant has to meet two legal tests:</p><p>- establishing, on a balance of probabilities, that the disablement was caused by a vaccination covered by the VDPS; and</p><p>- the resulting disablement is severe disablement (60% or more), assessed on the same basis as for the Industrial Injuries Disablement Benefit Scheme.</p><p> </p><p>Disablement is the overall effect of the disability arising from a loss of faculty caused by the vaccine. It is an assessment of the effects of the medical condition, not an assessment of the condition itself. The effects may be physical or mental or both. The level of disablement is made by comparison of the disabled person to a person of the same age and sex whose physical and mental condition is normal.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 15:44:36 answering member 4067 label Biography information for Steve Brine
tabling member	1522 label Biography information for Adam Holloway

1054839

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information he holds on research into safer alternatives to the Stamaril vaccine; and if the Government will provide funding for such research.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216216
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Medical Research Council has an active study to assess the safety and immunogenicity of yellow fever vaccine dose sparing strategies for campaign and programmatic use. The study seeks to determine whether using a fractional dose of the normal yellow fever vaccine in infants provides sufficient protection against yellow fever compared with the normal dose of vaccine and whether altering the route of administration affects vaccine safety.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 12/02/2019 16:59:08 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1054841

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made a recent assessment of the effectiveness of the regulatory regime in ensuring that drug companies continuously take steps to minimise the risks from their products.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216217
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>Holders of marketing authorisations are responsible for on-going monitoring of the safety of the medicinal products they place on the market. Additionally, the safety profile of all medicinal products is continually reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) to determine whether there are new risks, if risks have changed, and if any additional risk minimising measures or other regulatory action is required.</p><p> </p><p>Since 2012 it has been a legal requirement for both marketing authorisation holders and medicines regulators to monitor the effectiveness of all such risk minimising measures to determine whether they have had the desired effect. Depending on the findings, further action to minimise risk may be taken.</p><p> </p><p>Recent reviews of the impact of regulatory interventions have been conducted by the MHRA and across the European regulatory network, and further evaluation of the effectiveness of the regulatory regimen in the European Union is ongoing.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 12/02/2019 16:53:58 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1037194

registered interest
date	07/01/2019
answering body	Church Commissioners
answering dept id	9
answering dept short name	Church Commissioners
answering dept sort name	Church Commissioners
hansard heading	Cathedrals: Music
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Right Honourable Member for Meriden, representing the Church Commissioners, what duty does (a) the Church of England and (b) cathedrals and abbeys have to cathedral choristers with long-term medical conditions under disability discrimination legislation; and if she will make a statement.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	205855
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>The Church of England comprises a large number of legally separate institutions, which includes Cathedrals, Parochial Church Councils and Diocesan Boards of Finance. Each Cathedral, as an independent legal entity, is required to comply with the Equality Act 2010 (the “Act”) and so has a duty to make reasonable adjustments for disabled persons in accordance with the requirements of the Act. This duty applies in relation to a Cathedral chorister who has a disability for the purposes the Act (whether or not the disability is due to a long-term medical condition). However, there is no separate legal duty placed on cathedrals in relation to child choristers as a specific group.</p><p> </p><p>A cathedral has a duty to make reasonable adjustments to enable all persons with a disability to have physical access to the cathedral. As the Act does not override other legislation, such as listed building or planning legislation, the Church of England’s Cathedral and Church Buildings Division has produced a guidance note for cathedrals which specifically addresses this issue: <a href="https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.churchcare.co.uk%2Fimages%2Faccess_and_disabled_people.pdF&amp;data=02%7C01%7Csimon.stanley%40churchofengland.org%7C7f8f83476a3945a932d408d6770832c2%7C95e2463b3ab047b49ac1587c77ee84f0%7C0%7C0%7C636827274435002881&amp;sdata=7imeo07BtD%2FGlA%2FWyQvLQIpo0BL6cM%2FRwHm%2BKz6OYc0%3D&amp;reserved=0" target="_blank">http://www.churchcare.co.uk/images/access_and_disabled_people.pdF</a>. Common reasonable adjustments made by cathedrals include the removal of pews to allow greater flexibility of seating and use of space and the addition of ramps and/or the levelling of internal floors.</p><p> </p><p>The duty to make reasonable adjustments under the Act rests with individual cathedrals. What constitutes reasonable adjustment in the situation of choristers will depend on the nature of the particular disability and what may be considered to be reasonable in the circumstances. I understand that several cathedrals have successfully integrated choristers with disabilities into their choirs.</p> answering member constituency Meriden answering member printed Dame Caroline Spelman question first answered 10/01/2019 14:38:29 answering member 312 label Biography information for Dame Caroline Spelman
tabling member	1522 label Biography information for Adam Holloway